Cupric glycinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cupric glycinate
DrugBank Accession Number
DB11509
Background

Not Available

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 211.664
Monoisotopic: 210.978005
Chemical Formula
C4H8CuN2O4
Synonyms
  • Copper glycinate
  • Copper(II) biglycinate
  • Copper(II) diglycinate
  • Copper(II) glycinate
  • Cupric aminoacetate
  • Cupric glycinate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids
Alternative Parents
Carboxylic acid salts / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic zwitterions / Organic oxides / Organic copper salts / Monoalkylamines / Hydrocarbon derivatives
show 1 more
Substituents
Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic copper salt
show 11 more
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
68VAV8QID7
CAS number
13479-54-4
InChI Key
VVYPIVJZLVJPGU-UHFFFAOYSA-L
InChI
InChI=1S/2C2H5NO2.Cu/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2
IUPAC Name
copper(2+) bis(2-aminoacetate)
SMILES
[Cu++].NCC([O-])=O.NCC([O-])=O

References

General References
  1. Arthington JD, Corah LR, Blecha F: The effect of molybdenum-induced copper deficiency on acute-phase protein concentrations, superoxide dismutase activity, leukocyte numbers, and lymphocyte proliferation in beef heifers inoculated with bovine herpesvirus-1. J Anim Sci. 1996 Jan;74(1):211-7. [Article]
  2. Rabovsky AB, Komarov AM, Ivie JS, Buettner GR: Minimization of free radical damage by metal catalysis of multivitamin/multimineral supplements. Nutr J. 2010 Nov 23;9:61. doi: 10.1186/1475-2891-9-61. [Article]
  3. Szymanski P, Fraczek T, Markowicz M, Mikiciuk-Olasik E: Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals. 2012 Dec;25(6):1089-112. doi: 10.1007/s10534-012-9578-y. Epub 2012 Aug 23. [Article]
ChemSpider
2297544
RxNav
1428217

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility189.0 mg/mLALOGPS
logP-1.5ALOGPS
logP-3.4Chemaxon
logS-0.05ALOGPS
pKa (Strongest Acidic)2.31Chemaxon
pKa (Strongest Basic)9.24Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area66.15 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity26.84 m3·mol-1Chemaxon
Polarizability6.25 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at February 26, 2016 17:27 / Updated at June 12, 2020 16:53